Cargando…

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study

The objective of this study was to evaluate the efficacy and safety profile of weekly docetaxel, estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer. Forty-eight patients received 35 mg m(−2) of weekly docetaxel for 3 out of every 4 weeks, 280 mg of estramustine t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carles, J, Font, A, Mellado, B, Domenech, M, Gallardo, E, González-Larriba, J L, Catalan, G, Alfaro, J, Gonzalez del Alba, A, Nogué, M, Lianes, P, Tello, J M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360463/ https://www.ncbi.nlm.nih.gov/pubmed/17955053 http://dx.doi.org/10.1038/sj.bjc.6604030

Ejemplares similares

Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
por: Nakano, Kazuhiko, et al.
Publicado: (2012)

Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer
por: Galli, L, et al.
Publicado: (2007)

Estramustine binding protein and anti-proliferative effect of estramustine in human glioma cell lines.
por: von Schoultz, E., et al.
Publicado: (1988)

Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumours in humans.
por: Bergenheim, A. T., et al.
Publicado: (1993)

Effects of radiotherapy and estramustine on the microvasculature in malignant glioma
por: Johansson, M, et al.
Publicado: (1999)

Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient
por: Morita, Tatsuo
Publicado: (2010)

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer
por: Albrecht, W, et al.
Publicado: (2004)

Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.
por: Speicher, L. A., et al.
Publicado: (1991)

Comparison of Ketoconazole and Estramustine for Treating Patients with Castration-Resistant Prostate Cancer
por: Yun, Bu Hyeon, et al.
Publicado: (2011)

Computerized detection of morphological changes to glioma cells during estramustine and ion-channel blocker perifusion.
por: Behnam-Motlagh, P., et al.
Publicado: (1997)

Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study.
por: Hernes, E. H., et al.
Publicado: (1997)

Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer
por: Mellado, B, et al.
Publicado: (2009)

Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma
por: Zekri, J M, et al.
Publicado: (2003)

Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis
por: Qin, Zhiqiang, et al.
Publicado: (2016)

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer
por: Narita, Shintaro, et al.
Publicado: (2012)

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
por: Tebbutt, N C, et al.
Publicado: (2013)

SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)
por: Lázaro, M., et al.
Publicado: (2016)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
por: Sinibaldi, Victoria J
Publicado: (2007)

Estramustine Phosphate Inhibits TGF-β-Induced Mouse Macrophage Migration and Urokinase-Type Plasminogen Activator Production
por: Mojsilovic, Sonja S., et al.
Publicado: (2018)

Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
por: Joensuu, H., et al.
Publicado: (2010)

DNA fragmentation induced by the antimitotic drug estramustine in malignant rat glioma but not in normal brain--suggesting an apoptotic cell death.
por: Vallbo, C., et al.
Publicado: (1995)

Cytokinesis-block micronucleus assay of celecoxib and celecoxib derivatives
por: Reimann, Hauke, et al.
Publicado: (2020)

Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel
por: Jiménez, Natalia, et al.
Publicado: (2022)

A Phase II Study of Docetaxel in Patients with Relapsed and Refractory Ewing's Tumours
por: Meyer, T., et al.
Publicado: (2003)

Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma
por: Garcia-Recio, Marta, et al.
Publicado: (2018)

Celecoxib for Management of Refractory Back Pain Secondary to Vertebral Osteomyelitis: A Case Report
por: Glicksman, Michael, et al.
Publicado: (2021)

Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells
por: Tsakalozou, Eleftheria, et al.
Publicado: (2012)

EPCT-11. PHASE 1 STUDY OF FLUVASTATIN-CELECOXIB COMBINATION IN CHILDREN WITH RELAPSING/REFRACTORY OPTICO-CHIASMATIC LOW-GRADE GLIOMA OR HIGH-GRADE GLIOMAS (FLUVABREX): FINAL RESULTS
por: Andrew, Nicolas, et al.
Publicado: (2020)

Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells
Publicado: (1988)

Phase II study of ‘high-dose’ celecoxib and metronomic ‘low-dose’ cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma
por: Abdel-Bary, N, et al.
Publicado: (2009)

Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles
por: Kramer, G, et al.
Publicado: (2006)

Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
por: Xu, Jie, et al.
Publicado: (2018)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Celecoxib Analogues for Cancer Treatment: An Update on OSU-03012 and 2,5-Dimethyl-Celecoxib
por: Sobolewski, Cyril, et al.
Publicado: (2021)

Celecoxib: a selective cyclooxygenase-2 inhibitor
por: Gandelman, M
Publicado: (2003)

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
por: Allegrini, Giacomo, et al.
Publicado: (2012)

Challenges and Opportunities for Celecoxib Repurposing
por: Bąk, Urszula, et al.
Publicado: (2023)

Preparation and Evaluation of Amino Acid Conjugates of Celecoxib as Prodrugs to Improve the Pharmacokinetic and Therapeutic Properties of Celecoxib
por: Lee, Yonghyun, et al.
Publicado: (2020)

Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis
por: Lee, Ha-young, et al.
Publicado: (2012)

Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
por: Calcagno, Fabien, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0f2mt9739utr3m5i82hll1d7st